TROP2, the target of an FDA–approved antibody–drug conjugate in breast and bladder cancers (33, 34), was expressed in all PRADs and HGCs but not in the majority of NEPC samples (Figure 1H) nor in cells with expression of NEPC TFs (Supplementary Figure 1E). This evidence concerns the gene TACSTD2 and urinary bladder carcinoma.